食品药品监督管理局
溃疡性结肠炎
医学
炎症性肠病
疾病
药品
重症监护医学
克罗恩病
炎症性肠病
内科学
胃肠病学
药理学
作者
Shahrose Rahman,Ranish K. Patel,Elisa K. Boden,Vassiliki L. Tsikitis
标识
DOI:10.1016/j.suc.2023.12.005
摘要
The past few decades have seen significant advancements in the medical management of both ulcerative colitis (UC) and Crohn's disease (CD). The previous dependence on steroids is no longer an acceptable strategy following the Food and Drug Administration approval for several new classes of medication. These medications include aminosalicylates, immunomodulators , biologics, and oral targeted small-molecule inhibitors . This article highlights several key trials and discusses modern treatment paradigms for both UC and CD based on disease severity.
科研通智能强力驱动
Strongly Powered by AbleSci AI